Enanta Pharmaceuticals Inc. (NASDAQ:ENTA)‘s stock had its “outperform” rating reaffirmed by investment analysts at Robert W. Baird in a research note issued on Tuesday. They presently have a $27.00 target price on the stock, up from their previous target price of $22.00. Robert W. Baird’s price objective would indicate a potential downside of 18.53% from the stock’s current price.

Several other analysts also recently issued reports on ENTA. Zacks Investment Research downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 28th. JPMorgan Chase & Co. set a $26.00 price target on shares of Enanta Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. Enanta Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $27.29.

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) opened at 33.14 on Tuesday. The company’s 50 day moving average is $26.09 and its 200-day moving average is $24.14. Enanta Pharmaceuticals has a 12 month low of $20.39 and a 12 month high of $35.06. The company has a market cap of $630.82 million, a P/E ratio of 29.33 and a beta of 0.61.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, November 21st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.05. The business earned $12.80 million during the quarter, compared to the consensus estimate of $13.56 million. Enanta Pharmaceuticals had a net margin of 24.55% and a return on equity of 8.13%. Enanta Pharmaceuticals’s quarterly revenue was down 11.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.29 EPS. Analysts expect that Enanta Pharmaceuticals will post $1.08 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Enanta Pharmaceuticals by 295.7% in the second quarter. BlackRock Inc. now owns 4,614 shares of the company’s stock worth $102,000 after buying an additional 3,448 shares in the last quarter. Adams Diversified Equity Fund Inc. acquired a new position in shares of Enanta Pharmaceuticals during the second quarter worth about $194,000. Highbridge Capital Management LLC acquired a new position in shares of Enanta Pharmaceuticals during the third quarter worth about $215,000. BlackRock Group LTD boosted its position in shares of Enanta Pharmaceuticals by 7.9% in the second quarter. BlackRock Group LTD now owns 12,038 shares of the company’s stock worth $265,000 after buying an additional 882 shares in the last quarter. Finally, Texas Permanent School Fund boosted its position in shares of Enanta Pharmaceuticals by 4.3% in the third quarter. Texas Permanent School Fund now owns 10,586 shares of the company’s stock worth $282,000 after buying an additional 439 shares in the last quarter. Institutional investors own 65.40% of the company’s stock.

WARNING: This report was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of U.S. & international trademark & copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2016/11/24/enanta-pharmaceuticals-inc-enta-stock-rating-reaffirmed-by-robert-w-baird.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

5 Day Chart for NASDAQ:ENTA

Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.